Impact on urinary oxalate levels with use of ezetimibe.

ABSTRACT:

Background

Calcium oxalate stones are the most common cause of nephrolithiasis in the United States. Smaller studies of <15 patients investigating ezetimibe, a selective cholesterol absorption inhibitor, have suggested increased urine oxalate levels with use of the drug. We attempt to better define this relationship of ezetimibe on urinary oxalate using a larger patient sample analysing multiple urine collections on and off treatment.

Materials and methods

We retrospectively reviewed all consecutive patients from 01/2018 through 04/2019 evaluated for nephrolithiasis with use of ezetimibe documented in their medical record at Mayo Clinic Florida. Primary outcomes included increase in urinary oxalate with use of ezetimibe and reduction in urinary oxalate with discontinuation o

SUBMITTER: Trautman CL 

PROVIDER: S-EPMC8029507 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature